Arcus Biosciences, Inc. (NYSE:RCUS) COO Jennifer Jarrett Sells 11,551 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUSGet Free Report) COO Jennifer Jarrett sold 11,551 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $17.55, for a total transaction of $202,720.05. Following the completion of the transaction, the chief operating officer now directly owns 215,253 shares in the company, valued at approximately $3,777,690.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jennifer Jarrett also recently made the following trade(s):

  • On Monday, March 18th, Jennifer Jarrett sold 13,449 shares of Arcus Biosciences stock. The stock was sold at an average price of $17.92, for a total transaction of $241,006.08.
  • On Monday, February 26th, Jennifer Jarrett sold 24,555 shares of Arcus Biosciences stock. The stock was sold at an average price of $20.07, for a total transaction of $492,818.85.

Arcus Biosciences Trading Up 3.7 %

Arcus Biosciences stock opened at $18.88 on Friday. Arcus Biosciences, Inc. has a 1 year low of $12.95 and a 1 year high of $25.47. The firm’s 50 day moving average price is $17.17 and its 200-day moving average price is $16.96.

Arcus Biosciences (NYSE:RCUSGet Free Report) last announced its quarterly earnings results on Wednesday, February 21st. The company reported ($1.08) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.01. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The company had revenue of $31.00 million for the quarter, compared to analysts’ expectations of $28.30 million. During the same quarter in the previous year, the business posted ($0.93) earnings per share. Arcus Biosciences’s quarterly revenue was down 8.8% on a year-over-year basis. On average, equities analysts forecast that Arcus Biosciences, Inc. will post -3.59 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on RCUS. Truist Financial reissued a “buy” rating and issued a $50.00 price objective on shares of Arcus Biosciences in a report on Monday, March 25th. Mizuho decreased their target price on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, January 30th. Finally, Wedbush restated an “outperform” rating and set a $30.00 target price on shares of Arcus Biosciences in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.25.

View Our Latest Report on RCUS

Institutional Investors Weigh In On Arcus Biosciences

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Arcus Biosciences by 4.2% in the fourth quarter. Vanguard Group Inc. now owns 4,680,716 shares of the company’s stock worth $89,402,000 after purchasing an additional 186,898 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Arcus Biosciences by 0.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 592,291 shares of the company’s stock worth $11,313,000 after purchasing an additional 4,083 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Arcus Biosciences by 5.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 32,858 shares of the company’s stock worth $628,000 after purchasing an additional 1,645 shares during the last quarter. GSA Capital Partners LLP increased its position in Arcus Biosciences by 329.9% in the fourth quarter. GSA Capital Partners LLP now owns 90,873 shares of the company’s stock worth $1,736,000 after purchasing an additional 69,735 shares during the last quarter. Finally, Public Employees Retirement System of Ohio increased its position in Arcus Biosciences by 439.4% in the fourth quarter. Public Employees Retirement System of Ohio now owns 10,787 shares of the company’s stock worth $206,000 after purchasing an additional 8,787 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Further Reading

Insider Buying and Selling by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.